August 2018 Ample evidence shows methadone and buprenorphine reduce overdose deaths, prevent the spread of diseases like HIV, and enable people to take back their lives, but there are restrictions on who can prescribe these medications. Read More.
July 2018 This week, the Food and Drug Administration (FDA) approved Epidiolex (cannabidiol, or CBD), a medication extracted from marijuana, for the treatment of two severe pediatric seizure disorders. Read More.
June 2018 In spring 2018, Congress added an additional $500 million to the NIH budget to invest in science to find solutions to the opioid crisis. The funding that NIDA is receiving will go toward the goal of addressing addiction in new ways and better delivering existing forms of care to populations that need it. Read More.
May 2018 New data-gathering and analytic capabilities are enabling the kinds of massive, long-term studies needed to investigate genetic, environmental, and lifestyle factors that contribute to disease. Read More.
May 2018 Today, a new analysis in JAMA by epidemiologists at NIDA and the Substance Abuse and Mental Health Services Administration reveals the scope of the crisis, and the rapidity with which the opioid problem has broadened from prescription opioids and heroin to include their much more deadly synthetic cousins. Read More.
April 2018 One of the pillars of the current federal initiatives to end the opioid crisis is the development of new medications to treat opioid addiction. The FDA Patient-Focused Drug Development Initiative (PFDD), established in 2012, seeks to solicit patient perspectives on which symptoms are most important to target. Read More.
March 2018 Informed Americans no longer view addiction as a moral failing, and more and more policymakers are recognizing that punishment is an ineffective and inappropriate tool for addressing a person’s drug problems. Treatment is what is needed. Read More.
February 2018 A recent study published in Lancet found that extended-release naltrexone was equally effective at reducing illicit opioid use as the partial agonist buprenorphine if patients could be successfully initiated on naltrexone. Read More.